Business Context and Reporting Period
Company: Viking Therapeutics, Inc. (Nasdaq: VKTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Viking is a clinical-stage biopharmaceutical company focused on novel therapies for metabolic and endocrine disorders. Key programs include VK2735 (obesity, Phase 3), VK2809 (NASH/MASH, Phase 2b), and VK0214 (X-ALD, Phase 1b). The company has not generated any revenue to date.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(158,325) | $(45,629) |
| Net Loss Per Share (Basic & Diluted) | $(1.37) | $(0.41) |
| Research & Development Expenses | $150,150 | $41,391 |
| General & Administrative Expenses | $13,975 | $14,078 |
| Cash, Cash Equivalents & Short-Term Investments | $602,964 | $37,940 (Cash only) |
| Net Cash Used in Operating Activities | $(113,976) | $(52,331) |
| Net Cash Provided by Investing Activities | $54,189 | $63,245 |
| Net Cash Provided by Financing Activities | $12,077 | $349 |
Material Changes vs. Prior Period
- Significant Increase in R&D: Research and development expenses surged 263% to $150.2 million, primarily driven by $103.2 million in increased clinical study costs for the VK2735 Phase 3 VANQUISH-1 and VANQUISH-2 trials.
- Widened Net Loss: Net loss increased to $158.3 million from $45.6 million year-over-year, reflecting the accelerated clinical development spend.
- Interest Income Decline: Total other income decreased 41% to $5.8 million due to lower average cash balances compared to the prior year.
- Financing Activity: The company raised $11.6 million net from an At-The-Market (ATM) offering in Q1 2026, compared to no ATM proceeds in Q1 2025.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes current cash, cash equivalents, and short-term investments of approximately $603 million are sufficient to fund operations through at least June 30, 2027. The company expects to continue incurring significant losses as it advances clinical trials.
Material Contingency (Ligand Dispute): On April 24, 2026, Ligand Pharmaceuticals notified Viking of its intent to terminate the license for the TR-Beta Program (including the VK2809 candidate) effective May 4, 2026. Viking disputes this termination, asserting Ligand has no right to terminate, and intends to vigorously defend its rights. This dispute poses a significant risk to the development of VK2809.
Operational Updates:
- Completed enrollment in VK2735 Phase 3 VANQUISH-1 (Nov 2025) and VANQUISH-2 (Mar 2026).
- Announced positive Phase 2 results for oral VK2735 (Aug 2025).
- Filed IND for VK3019 (Novel Amylin Agonist) in April 2026; Phase 1 trial planned for Q2 2026.
- CEO Brian Lian adopted a Rule 10b5-1 trading plan for 365,000 shares.
Investor Verification Checklist
- Ligand License Status: Verify the current legal status of the dispute regarding the TR-Beta Program license termination and potential impact on the VK2809 pipeline.
- Cash Burn Rate: Confirm the sustainability of the $114 million quarterly operating cash burn against the $603 million liquidity position.
- Phase 3 Trial Progress: Monitor enrollment and data readout timelines for the VK2735 VANQUISH-1 and VANQUISH-2 studies.
- ATM Offering Capacity: Note that $63.7 million remains available under the current ATM prospectus.
- Manufacturing Prepayments: Review the schedule and impact of prepayments to CordenPharma for VK2735 API and fill/finish capacity (2026-2028).